Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Wang, Yaw Cheng ^a,b   Sung, Wen Wei ^a   Wu, Tzu Chin ^a,b   Wang, Lee ^a   Chien, Wen Pin ^c   Cheng, Ya Wen ^a   Chen, Chih Yi ^d   Shieh, Shwn Huey ^e   Lee, Huei ^a,b,f  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c Center for Drug Evaluation   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; MESSENGER RNA;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INFILTRATION; CANCER PATIENT; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CELL SURVIVAL; CONCENTRATION (PARAMETERS); DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HAPLOTYPE; HUMAN; HUMAN TISSUE; IMMUNOSURVEILLANCE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALIDITY; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; T LYMPHOCYTE; TUMOR CELL;

AGED; ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HAPLOTYPES; HUMANS; INTERLEUKIN-10; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; NEOPLASMS, EXPERIMENTAL; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROMOTER REGIONS, GENETIC; SURVIVAL RATE; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 84864410008     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039525     Document Type: Article

References (43)

1. Mosser DM, Zhang X,((2008)) Interleukin-10: new perspectives on an old cytokine. Immunol Rev 226:: 205--218.
2. Saraiva M, O'Garra A,((2010)) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10:: 170--181.
3. O'Garra A, Vieira P,((2007)) T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol 7:: 425--428.
4. Kim R, Emi M, Tanabe K, Arihiro K,((2006)) Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 66:: 5527--5536.
5. Brooks DG, Ha SJ, Elsaesser H, Sharpe AH, Freeman GJ, et al.((2008)) IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc Natl Acad Sci U S A 105:: 20428--20433.
6. Seifart C, Plagens A, Dempfle A, Clostermann U, Vogelmeier C, et al.((2005)) TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers 21:: 157--165.
7. Shih CM, Lee YL, Chiou HL, Hsu WF, Chen WE, et al.((2005)) The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung Cancer 50:: 291--297.
8. Hart K, Landvik NE, Lind H, Skaug V, Haugen A, et al.((2011)) A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. Lung Cancer 71:: 123--129.
9. Faupel-Badger JM, Kidd LC, Albanes D, Virtamo J, Woodson K, et al.((2008)) Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control 19:: 119--124.
10. Eskdale J, Keijsers V, Huizinga T, Gallagher G,((1999)) Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun 1:: 151--155.
11. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, et al.((1997)) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:: 1--8.
12. Todaro M, Zerilli M, Ricci-Vitiani L, Bini M, Perez Alea M, et al.((2006)) Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. Cancer Res 66:: 1491--1499.
13. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, et al.((2008)) Interleukin-10-1082 promoter polymorphism associated with gastric cancer among Asians. Eur J Cancer 44:: 2648--2654.
14. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, et al.((2002)) Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62:: 3369--3372.
15. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, et al.((2006)) Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 66:: 4525--4530.
16. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, et al.((2006)) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 7:: 27--38.
17. Kube D, Hua TD, von Bonin F, Schoof N, Zeynalova S, et al.((2008)) Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study. Clin Cancer Res 14:: 3777--3784.
18. Cacev T, Radosevic S, Krizanac S, Kapitanovic S,((2008)) Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis 29:: 1572--1580.
19. Gerger A, Renner W, Langsenlehner T, Hofmann G, Knechtel G, et al.((2010)) Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res Treat 119:: 701--705.
20. Giacomelli L, Gianni W, Belfiore C, Gandini O, Repetto L, et al.((2003)) Persistence of epidermal growth factor receptor and interleukin 10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse. Clin Cancer Res 9:: 2678--2682.
21. Zheng C, Huang D, Liu L, Wu R, Bergenbrant Glas S, et al.((2001)) Interleukin-10 gene promoter polymorphisms in multiple myeloma. Int J Cancer 95:: 184--188.
22. Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, et al.((2004)) Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 103:: 3529--3534.
23. Zeni E, Mazzetti L, Miotto D, Lo Cascio N, Maestrelli P, et al.((2007)) Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J 30:: 627--632.
24. Soria JC, Moon C, Kemp BL, Liu DD, Feng L, et al.((2003)) Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 9:: 1785--1791.
25. Lu C, Soria JC, Tang X, Xu XC, Wang L, et al.((2004)) Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol 22:: 4575--4583.
26. De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, et al.((2000)) Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 117:: 365--373.
27. Hatanaka H, Abe Y, Kamiya T, Morino F, Nagata J, et al.((2000)) Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol 11:: 815--819.
28. Wang R, Lu M, Zhang J, Chen S, Luo X, et al.((2011)) Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer. J Exp Clin Cancer Res 30:: 62.
29. Montuenga LM, Pio R,((2007)) Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10. Eur Respir J 30:: 608--610.
30. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, et al.((1999)) Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 30:: 526--530.
31. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, et al.((1998)) Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A 95:: 9465--9470.
32. Font J, Garcia-Carrasco M, Ramos-Casals M, Aldea AI, Cervera R, et al.((2002)) The role of interleukin-10 promoter polymorphisms in the clinical expression of primary Sjogren's syndrome. Rheumatology (Oxford) 41:: 1025--1030.
33. Lin MT, Storer B, Martin PJ, Tseng LH, Gooley T, et al.((2003)) Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 349:: 2201--2210.
34. Lee JJ, Kim DH, Lee NY, Sohn SK, Kim JG, et al.((2007)) Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas. Br J Haematol 137:: 329--336.
35. Weng KP, Hsieh KS, Hwang YT, Huang SH, Lai TJ, et al.((2010)) IL-10 polymorphisms are associated with coronary artery lesions in acute stage of Kawasaki disease. Circ J 74:: 983--989.
36. Rad R, Dossumbekova A, Neu B, Lang R, Bauer S, et al.((2004)) Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection. Gut 53:: 1082--1089.
37. Sung WW, Wang YC, Cheng YW, Lee MC, Yeh KT, et al.((2011)) A Polymorphic-844T/C in FasL Promoter Predicts Survival and Relapse in Non-Small Cell Lung Cancer. Clin Cancer Res.
38. Hung CF, Cheng WF, He L, Ling M, Juang J, et al.((2003)) Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res 63:: 2393--2398.
39. Jarnicki AG, Lysaght J, Todryk S, Mills KH,((2006)) Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 177:: 896--904.
40. Aborsangaya KB, Dembinski I, Khatkar S, Alphonse MP, Nickerson P, et al.((2007)) Impact of aboriginal ethnicity on HCV core-induced IL-10 synthesis: interaction with IL-10 gene polymorphisms. Hepatology 45:: 623--630.
41. Suarez A, Castro P, Alonso R, Mozo L, Gutierrez C,((2003)) Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 75:: 711--717.
42. Diaz-Valdes N, Basagoiti M, Dotor J, Aranda F, Monreal I, et al.((2011)) Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. Cancer Res 71:: 812--821.
43. Hagenbaugh A, Sharma S, Dubinett SM, Wei SH, Aranda R, et al.((1997)) Altered immune responses in interleukin 10 transgenic mice. J Exp Med 185:: 2101--2110.